Skybiotech Healthcare Limited
Incorporated in 1983, Skybiotech Healthcare Ltd is in the business of Textile and Pharmaceuticals[1]
- Market Cap ₹ 26.6 Cr.
- Current Price ₹ 139
- High / Low ₹ 237 / 127
- Stock P/E
- Book Value ₹ 47.0
- Dividend Yield 0.00 %
- ROCE %
- ROE -26.4 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 2.96 times its book value
- Company has low interest coverage ratio.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Consumer Discretionary Textiles Textiles & Apparels Other Textile Products
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 0.00 | 6.96 | 7.85 | |
| 0.12 | 9.21 | 9.40 | |
| Operating Profit | -0.12 | -2.25 | -1.55 |
| OPM % | -32.33% | -19.75% | |
| 2.00 | 0.38 | 0.04 | |
| Interest | 0.00 | 0.01 | -0.11 |
| Depreciation | 0.00 | 0.54 | 0.53 |
| Profit before tax | 1.88 | -2.42 | -1.93 |
| Tax % | 18.09% | -2.07% | |
| 1.54 | -2.37 | -1.81 | |
| EPS in Rs | 8.04 | -12.38 | -8.87 |
| Dividend Payout % | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -254% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 57% |
| 1 Year: | -41% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | -26% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 1.92 | |
| Reserves | 7.07 | |
| 7.20 | ||
| 3.91 | ||
| Total Liabilities | 20.10 | |
| 12.03 | ||
| CWIP | 0.00 | |
| Investments | 2.46 | |
| 5.61 | ||
| Total Assets | 20.10 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| -1.04 | ||
| -9.63 | ||
| 1.24 | ||
| Net Cash Flow | -9.43 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 22.03 | |
| Inventory Days | ||
| Days Payable | ||
| Cash Conversion Cycle | 22.03 | |
| Working Capital Days | -18.88 | |
| ROCE % |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
16 Jan - Compliance certificate Under Reg. 74(5) of SEBI (DP) Regulation, 2018 for the quarter ended on 31st December, 2025
- Closure of Trading Window 27 Dec 2025
-
Revised Financial Results For The Quarter Ended On 30Th September, 2025
20 Nov 2025 - Board approved unaudited standalone and consolidated results for half-year ended Sep 30, 2025; revised filing added missing consolidated statements.
-
Financial Result For Quarter Ended On 30Th September, 2025
15 Nov 2025 - Board approved unaudited standalone and consolidated results for half-year ended Sept 30, 2025; limited review noted.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On 14Th November, 2025
15 Nov 2025 - Approved unaudited standalone and consolidated H1 results for Sep 30, 2025; limited review recorded.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2008
from bse
-
Financial Year 2007
from bse
-
Financial Year 2002
from bse
Business Overview:[1]
SBHCL was engaged in the Textile business and was not generating any revenue from its main business activity. It acquired 72.52% stake in M/s. Skybiotech Lifescience Private Limited which become their subsidiary and is engaged in manufacturing Pharmaceutical Products and ingredients